10-Q/A: Polomar Health Services Restates Q3 2024 Financials Following SEC Comments, Adjusts Acquisition Accounting

Polomar Health Services files an amended quarterly report (Form 10-Q/A) to address SEC comments, primarily concerning net loss per share calculations, fair market value assessment of acquired assets, revenue recognition policy expansion, and a change in accounting treatment for the Polomar Specialty Pharmacy acquisition.

Summary

• Polomar Health Services has filed an amendment to its quarterly report on Form 10-Q for the period ended September 30, 2024.
• The amendment addresses comments received from the SEC regarding adjustments to the weighted average number of shares used in net loss per common share calculations for the three and nine months ended September 30, 2023.
• It also includes a further explanation of the basis for recording fair market value for the acquisition of certain assets and an expansion of the company's revenue recognition policy.
• The company has changed the accounting treatment of its acquisition of Polomar Specialty Pharmacy, LLC, determining it was a recapitalization rather than a reverse merger.
• The company's principal executive officer and principal financial officer have filed new certifications as required by the Securities Exchange Act of 1934.
• The company's cash balance as of September 30, 2024, was $16,202, compared to $8,808 at the end of 2023.
• The company's revenue for the three months ended September 30, 2024, was $9,849, compared to $21,457 for the same period in 2023.
• The company's net loss for the three months ended September 30, 2024, was $271,333, compared to $172,163 for the same period in 2023.
• The company's revenue for the nine months ended September 30, 2024, was $37,954, compared to $24,556 for the same period in 2023.
• The company's net loss for the nine months ended September 30, 2024, was $622,544, compared to $383,780 for the same period in 2023.
• The company has an accumulated deficit of $2,192,373 as of September 30, 2024.
• The company's management has determined that substantial doubt exists about the company's ability to continue as a going concern.
• The company is authorized to issue 295,000,000 shares of common stock with a par value of $0.001 as of September 30, 2024.
• The company is also authorized to issue 500,000 shares of preferred stock with a par value of $0.001, of which 500,000 are designated as Series A Preferred Stock as of September 30, 2024.

Sentiment

Score: 3

Explanation: The document contains several negative indicators, including increased net losses, decreased revenue, an accumulated deficit, and management's doubt about the company's ability to continue as a going concern. While there are some positive developments, such as the reverse merger and new business ventures, the overall sentiment is negative due to the company's financial instability.

Positives

• The company's cash balance increased from the end of 2023.
• The company completed a reverse merger with Polomar Specialty Pharmacy, which is expected to provide new revenue streams.
• The company acquired SlimRxTM, a weight loss focused online platform, as part of the merger.
• The company expects to launch PoloMedsTM during the fourth quarter of 2024.
• The company entered into a Know How and Patent License Agreement with Pinata Holdings, Inc. for the proprietary delivery of products containing certain ingredients.
• The company is actively seeking approval and authorization in other states and expects to be able to provide prescription medications in a majority of U.S. states by the end of 2025.

Negatives

• The company's revenue decreased compared to the same periods in the previous year.
• The company's net loss increased compared to the same periods in the previous year.
• The company has an accumulated deficit of $2,192,373 as of September 30, 2024.
• The company's management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has material weaknesses in internal control over financial reporting.

Risks

• The company's management has expressed substantial doubt about the company's ability to continue as a going concern.
• The company has not generated material revenues from operations.
• The company has incurred losses since inception and negative cash flows from operating activities for all periods presented.
• The company has material weaknesses in internal control over financial reporting.
• The company requires additional working capital for ongoing operating expenses.
• There is no guarantee the company will raise sufficient capital to continue operations.
• The company is subject to legislative or regulatory changes concerning platforms with data about companies.
• The company faces uncertainty with respect to intellectual property rights, protecting those rights and claims of infringement of others intellectual property.
• The company faces competition.
• The company faces cybersecurity concerns.

Future Outlook

The company plans to raise additional capital and invest its working capital resources in its newly acquired business from Polomar and in other potential business opportunities. The Company is also actively seeking approval and authorization in other states and expects to be able to provide prescription medications in a majority of U.S. states by the end of 2025. The Company also anticipates applying for a drug export permit in early 2025.

Management Comments

• Management evaluated all relevant conditions and events that are reasonably known or reasonably knowable, in the aggregate, as of the date the consolidated financial statements are issued and determined that substantial doubt exists about the Company's ability to continue as a going concern.

Industry Context

The company's shift to operating Polomar Specialty Pharmacy reflects a move into the pharmaceutical compounding industry, which is subject to specific regulations and market dynamics. The acquisition of SlimRx and the planned launch of PoloMeds indicate a focus on telehealth and online prescription fulfillment, aligning with the growing trend of digital healthcare. The company's business model of providing prescription fulfillment services for third-party telehealth platforms positions it within the broader telehealth ecosystem.

Comparison to Industry Standards

• Given the limited financial data provided, a comprehensive comparison to industry standards is challenging.
• However, the company's focus on specialty pharmacy and telehealth aligns with trends observed in companies like Teladoc Health and GoodRx, which have seen significant growth in recent years.
• The company's reliance on related-party debt for financing is a common practice for early-stage companies but may raise concerns about financial stability and independence.
• The company's management's expression of substantial doubt about the company's ability to continue as a going concern is a significant concern and highlights the need for improved financial performance and capital raising efforts.
• The company's material weaknesses in internal control over financial reporting are also a concern and require remediation to ensure the accuracy and reliability of financial information.

Related Party Transactions

• During the nine months ended September 30, 2024, Trustfeed and Polomar borrowed an aggregate of $821,425 from a related party for payment of operating expenses.
• On August 13, 2024, Reprise Management, Inc., a California corporation affiliated with CWR (Reprise), issued an unsecured promissory note to Polomar (the Polomar Note), pursuant to which Polomar could borrow up to an aggregate principal amount of $700,000.
• Effective August 16, 2024, Trustfeed entered into a Promissory Note and Loan Agreement (the Trustfeed Note), as the borrower, with CWR, as the lender.
• Pinata is an affiliate of CWR.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be affected by potential cost-cutting measures or restructuring efforts.
• Customers may experience disruptions in service if the company's financial situation worsens.
• Suppliers and creditors face increased risk of non-payment.
• The company's ability to execute its business plan and achieve its growth objectives is uncertain.

Next Steps

• The company plans to raise additional capital.
• The company plans to invest its working capital resources in its newly acquired business from Polomar and in other potential business opportunities.
• The company expects to launch PoloMedsTM during the fourth quarter of 2024.
• The company is actively seeking approval and authorization in other states and expects to be able to provide prescription medications in a majority of U.S. states by the end of 2025.
• The company anticipates applying for a drug export permit in early 2025.
• The company needs to remediate material weaknesses in internal control over financial reporting.

Key Dates